Recent progress in 5-HT₆ receptor antagonists for the treatment of CNS diseases

Bibliography

• HOYER D, CLARKE DE, FOZARD JR et al.: International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotoniu). Pharmacological Rev (1993) 46:157–203.
   Web of Science ®Google Scholar
• KOHEN R, METCALF MA, KHAN N et al.: Cloning, characterization, and chromosomal localization of a human 5-HT6serotonin receptor. j Neurochem. (1996) 66:47–56
   PubMed Web of Science ®Google Scholar
• 3-SEBBEN M, ANSANAY H, BO CKAERT J etal.: 5-HT6receptors positively coupled to adenylyl cyclase in striatal neurones in culture. Neuroreport. (1994) 5:2553.
   Google Scholar
• SLEIGHT AJ, BOESS FG, BIDS M et al: The 5-hydroxytryptamine6receptor: localisation and function. Expert Opin. Ther. Patents (1998) 8(10):1215–1222.
   Web of Science ®Google Scholar
• •This review describes cloning, localisation, pharmacology, in vitro and in vivo functional correlates of the 5-HT6 receptor, as well as characterisation of Ro 04–6790 and Ro 63–0563 as potent and selective 5-HT6 receptor antagonists.
   Google Scholar
• SLEIGHT AJ, BOESS FG, BOURSON A etal.: 5-HT6and 5-HT7receptors: molecular biology, functional correlates and possible therapeutic indications. Dug News Perspect. (1997) 10 (4):214–224.
   Google Scholar
• •This review highlights that selective ligands for both 5-HT6 and 5-HT7 receptors may have clinical potential, and the development of selective compounds to examine these possibilities is highly desirable.
   Google Scholar
• BRANCHEK TA, BLACKBURN TP: 5-HT6Receptors as emerging targets for drug discovery. Ann. Rev Pharmacol Toxicol (2000) 40:319–334.
   PubMed Web of Science ®Google Scholar
• REAVILL C, ROGERS DC: The therapeutic potential of 5-HT6 receptor antagonists. Curr. Opin. Investig. Drugs (2001) 2(1):104–109.
   PubMedGoogle Scholar
• ••An excellent review summarising the recentliterature evaluations of the most studied 5-HT6 receptor potent and selective antagonists SB-271046, SB-258585, Ro 04–6790 and Ro 63–0563.
   Google Scholar
• BARNES NM, SHARP T: A review of central 5-HT receptors and their function. Neuropharmacology (1999) 38:1083–1152.
   PubMed Web of Science ®Google Scholar
• •An excellent review of the various serotonin receptor subtypes highlighting their distribution.
   Google Scholar
• HOYER D, MARTIN G: 5-HT receptor classification and nomenclature: towards a harmonization with the human genome. Neuropharmacology (1997) 36:419–428.
   PubMed Web of Science ®Google Scholar
• WARD RP HAMBLIN MW SIBLEY DR et al.: Localization of serotonin subtype 6 receptor messenger RNA in the rat brain by in situ hybridization histochemistry. Neurosience (1995) 64:1105–1111.
   PubMed Web of Science ®Google Scholar
• MONSMA FJ, SHEN Y, WARD RP et al: Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Ma Pharmacol. (1993) 43:320–327.
   PubMed Web of Science ®Google Scholar
• SHEN Y, SIBLEY DR, MELTZER HY et al.: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. Pharmacol Esp. Ther (1994) 268:1403–1410.
   PubMed Web of Science ®Google Scholar
• BOURSON A, BORRONI E, AUSTIN R et al.: Determination of the role of the 5-HT6 receptor in the rat brain: a study using antisense oligonucleotides. Pharmacol Esp. Ther (1995) 274:173–180.
   PubMed Web of Science ®Google Scholar
• BOURSON A, BORRONI E, AUSTIN RH et al.: Effects of altered 5-HT6 expression in the rat: functional studies using antisense oligonucleotides. Behav. Brain Res. (1996) 73:245–248.
   PubMed Web of Science ®Google Scholar
• HUEZO-DIAZ P, DEMSPTER DB, GUTIERREZ B et al: Serotonin-6 (5-HT6) receptor variant association study with clozapine and olanzapine response. Schizophr. Res. (2001) 49:(1-2)71.
   Google Scholar
• VOGT IR, SHIMRON-ABARBANELL D, NEIDT H et al: Investigation of the human serotonin 6 (5-HT6) receptor gene in bipolar affective disorder and schizophrenia. Am. Med. Genet. (2000) 96:217–221.
   PubMed Web of Science ®Google Scholar
• BOURSON A, BOESS FG, BIDS M et al: Involvement of 5-HT receptors in nigro-striatal function in rodents. Br j Pharmacol (1998) 125:1562–1566.
   PubMed Web of Science ®Google Scholar
• ROUTLEDGE C, PRICE GW, BROMIDGE SM: Characterisation of SB-271046, a potent 5-HT6receptor antagonist. Br. J. Pharmacol (1999) 127:21P.
   Web of Science ®Google Scholar
• ROGERS DC, ROBINSON TL, QUILTER CA etal.: Cognitive enhancement effects of the selective 5-HT6 antagonist SB-271046. Br j Pharmacol (1999) 127:22P.
   Google Scholar
• SLEIGHT AJ: Co-localisation of 5-HT6 receptors on GABAergic but not cholinergic neurones in the adult brain. Serotonin satellite Book of Abstract for Society for Neuroscience Meeting. Nov. 2–3, New Orleans (2000) Abstract 94.
   Google Scholar
• FONE KCF: The 5-HT6 Receptor: potential CNS functions. Br j Pharmacol (2000) 131:238P.
   Web of Science ®Google Scholar
• WOOLLEY ML, MARSDEN CA, SLEIGHT AJ, FONE KCF: Reversal of a scopolamine-induced deficit in object discrimination by a selective 5-HT6 receptor antagonist, Ro-046790, in rats. Br. Pharmacol (2000) 129:64P.
   Web of Science ®Google Scholar
• WOOLLEY ML, BENTLEY JC, SLEIGHTAJ et al: A role for 5-HT6receptors in retention of spatial learning in the Morris water maze. Neuropharmacology (2001) 41:210–219.
   PubMed Web of Science ®Google Scholar
• DAWSON LA, NGUYEN HQ, LIP: In vivo effects of the 5-HT6antagonist SB-271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5-HT glutamate and aspartate. Br j Pharmacol (2000) 130:23–26.
   PubMed Web of Science ®Google Scholar
• DEAKIN JFW: Glutamate, GABA and cortical circuitry in schizophrenia. In: The Psychopharmacology of Schizophrenia. Reveley MA, Deakin JFW (Eds), Amold, London (2000)56–70.
   Google Scholar
• ROUTLEDGE C, BROMIDGE SM, MOSS SF et al.: Characterization of SB-271046: a potent, selective and orally active 5-HT6receptor antagonist. Br I Pharmacol (2000) 130: 1606-1612.
   Google Scholar
• UPTON N, STEAN T, MIDDLEMISS D etal.: Studies on the role of the 5-HT2c and 5-HT2Breceptors in regulating generalised seizure threshold in rodents. Eur. Pharmacol (1998) 359:33–40.
   Google Scholar
• JAVIER J, HIDALGO M: SB-271046 SmithKline Beecham. Curr. Opin. Investig. Drugs. (2001) 2(1):118–122.
   PubMedGoogle Scholar
• DAWSON LA, NGUYEN HQ, LIP: The 5-HT6 Receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. Neuropsychopharmacology (2001) 25(5).662–668.
   PubMed Web of Science ®Google Scholar
• DEMCHYSHYN LL, WILSON JM, MACLEAN NA etal.: ALX-1161: Pharmacological properties of a potent and selective 5-HT6receptor antagonist. Soc. Neurosci. (2001) Abstract 266.6.
   Google Scholar
• DEMCHYSHYN LL, O'BRIEN MA, EDWARDS LG et al: Pharmacological properties of 3-11\1-methyl piperidinel-N-indole derivatives as potent and selective 5-HT6receptor antagonists. Soc. Neurosci. (2000) Abstract 810.15.
   Google Scholar
• ISAAC M, SLASSI A, XIN T et al.: 6-Bicyclopiperaziny1-1-arylsulfonylindoles and 6-bicyclopiperidiny1-1-arylsulfonylindoles derivatives as novel, potent, and selective 5-HT6receptor antagonists. Bioorg. Med. Chem. Lett. (2000) 10:1719–1721.
   PubMedGoogle Scholar
• SLASSI A, O'BRIEN A, EDWARDS L et al.: 5-fluoro (A 3 (N methypyrrolidin-2-yl-methy9-1-arylindole derivatives as novel, potent h5-HT6serotonin receptor ligands. Bioorg. Med. Chem. Lett. (2002) In press.
   Google Scholar
• TSAI Y, DUKAT M, SLASSI A et al.: N1-(benzenesulfonyl)tryptamines as Novel 5-HT6 antagonists. Bioorg. Med. Chem. Lett. (2000) 10:2295–2299.
   PubMed Web of Science ®Google Scholar
• GLENNON RA, BONDAREV M, ROTH B: 5-HT6serotonin receptor binding of indolealkylamines: a preliminary structure-affinity investigation. Med. Chem. Res. (1999) 9(2):108–117.
   Web of Science ®Google Scholar
• LEE M, RANGISETTY JB, DUKAT M et al.: 5-HT6serotonin receptor binding affinities of N1-benzenesulfonyl and related tryptamines. Med. Chem. Res. (2000) 10:230–242.
   Web of Science ®Google Scholar
• GLENNON RA, LEE M, RANGISETTY JB et al.: 2-Subsituted tryptamines: agents with selectivity for 5-HT6serotonin receptors. J. Med. Chem. (2000) 43:1011–1018.
   PubMed Web of Science ®Google Scholar
• SLEIGHT AJ, BOESS FG, BIDS M et al.: Characterization of Ro 04-6790 and Ro 63-0563: potent and selective antagonists at human and rat 5-HT6receptors. Br j Pharmacy]. (1998) 124:556–562.
   PubMed Web of Science ®Google Scholar
• BOESS FG, RIEMER C, BIDS M etal.: The selective 5-HT6receptor radioligand l3F111Ro 63–0563 labels 5-HT6receptor binding site in rat and porcine striatum. Mol. Pharmacol. (1998) 54:577–583.
   Google Scholar
• BIDS M, SLEIGHT AJ, GODEL T et al.: 5-HT6receptor antagonists: lead optimisation and biological evaluation of N-aryl and N-heteroaryl 4-amino-benzene sulfonamides. Eur. J. Med. Chem. (2001) 36:165–178.
   PubMed Web of Science ®Google Scholar
• SLEIGHT AJ, BOESS FG, BIDS M et al.: Characterization of Ro 04-6790 and Ro 63-0563: potent and selective antagonists at human and rat 5-HT6 receptors. Br. Pharmacy]. (1998) 124:556–562.
   PubMed Web of Science ®Google Scholar
• BOESS FG, RIEMER C, BIDS M et al.: The 5-hydroxytryptamine, receptor-selective radioligand [1-1-31Ro 63-0563 labels 5-hydroxytryptamine receptor binding sites in rat and porcine striatum. Mol. Pharmacol. (1998) 54:577–583.
   PubMed Web of Science ®Google Scholar
• BENTLEY JC, FONE KCF, MARSDEN CA et al.: Stretching behaviour induced by the potent and selective 5-HT6 antagonist Ro 04–6790 in rats. IUPHAR (1998) (Munich).
   Google Scholar
• WOOLLEY ML, BENTLEY JC, SLEIGHT AJ et al.: A role for 5-HT6 receptors in retention of spatial learning in the Morris water maze. Neuropharmacology (2001) 41(2):210–219.
   PubMed Web of Science ®Google Scholar
• BENTLEY JC, BOURSON A, BOESS FG et al.: Investigation of stretching behaviour induced by the selective 5-HT6 receptor antagonist, Ro 04-6790, in rats. Br Pharmacy]. (1999) 126:1537–1542.
   PubMed Web of Science ®Google Scholar
• BROMIDGE SM, BROWN AM, CLARKE SE etal.: 5-Chloro-N-(4-methoxy-3-piperazin 1 yl pheny1)-3-methy1-2-benzothiophenesulfonamide (SB-271046): a potent, selective and orally bioavailable 5-HT6 receptor antagonist. Med. Chem. (1999) 42:202–205.
   Google Scholar
• ••Excellent communications describing SARand pharmacoltinetic studies of a series of potent and selective N-methylpiperazines for 5-HT6 receptor, leading to the clinical candidate SB–271046.
   Google Scholar
• BROMIDGE SM, GRIFFITH K, HEIGHTMAN TD et al.: Novel (4-piperazin-1-ylquinolin -6-y9 arylsulfonamides with high affinity and selectivity for the 5-HT6 receptor. Bioorg. Med. Chem. Lett. (2001) 11:2843–2846.
   PubMed Web of Science ®Google Scholar
• BROMIDGE SM, CLARKE SE, GAGER T et al.: Phenyl benzenesulfonamides are novel and selective 5-HT6 antagonists: identification of N-(2,5-dibromo-3-fluoropheny1)-4-methoxy-3-piperazin-1-ylbenzenesulfonamide (SB-357134). Bioorg. Med. Chem. Lett. (2001) 11:55–58.
   PubMed Web of Science ®Google Scholar
• HIRST WD, MINTON JAL, BROMIDGE SM etal.: Characterization of [12511-SB-258585 binding to human recombinant and native 5-HT6 receptors in rat, pig and human brain tissue. Br Pharmacy]. (2000) 130:1597–1605.
   Google Scholar
• RUSSEL M, BAKER R, BARDEN L et al.:N-arylsulfonylindole derivatives as serotonon 5-HT6 receptor ligands. j Med. Chem. (2001) 44:3881–3895.
   PubMed Web of Science ®Google Scholar